Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Durvalumab and Consolidation SBRT Following Chemoradiation for Locally Advanced Stage III Non-Small Cell Lung (358)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03589547
Recruitment Status : Recruiting
First Posted : July 18, 2018
Last Update Posted : January 23, 2020
Sponsor:
Collaborators:
Brown University
Lifespan
Information provided by (Responsible Party):
Hina Khan, Brown University

Brief Summary:

Durvalumab is a drug that stimulates the immune system to fight lung cancer. Durvalumab is FDA approved to treat lung cancer. Stereotactic body radiation therapy (SBRT) is a newer radiation treatment that gives fewer, but higher doses of radiation than standard radiation.

With SBRT, radiation is focused toward the cancer and away from normal surrounding lung tissue. It is possible that when cancer cells are damaged by SBRT Durvalumab may be more effective in activating the immune system. SBRT is a standard FDA approved treatment for early stage (stage 1) lung cancer and is investigational in patients such as yourself with stage 3 lung cancer. The combination of Durvalumab and SBRT is investigational. This study will investigate the effects, good and bad, of the combination of Durvalumab and SBRT.


Condition or disease Intervention/treatment Phase
Stage III Non-small-cell Lung Cancer Drug: Durvalumab Radiation: SBRT Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 25 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Durvalumab and Consolidation SBRT Following Chemoradiation for Locally Advanced Stage III Non-Small Cell Lung
Actual Study Start Date : May 13, 2019
Estimated Primary Completion Date : October 2020
Estimated Study Completion Date : October 2025

Resource links provided by the National Library of Medicine

Drug Information available for: Durvalumab

Arm Intervention/treatment
Experimental: Durvalumab and SBRT

Durvalumab 10mg/kg x 1 day, dose #1 to occur > 3 weeks and <7 weeks after last chemo/RT and prior to SBRT dose 1 (5-10 day time frame between Durvalumab and SBRT).

SBRT boost will consist of 2 fractions delivered to the primary tumor only, over 1-2 weeks between the first and second treatments with durvalumab (see above for time frames). The dose will consist of 20Gy (2 fractions of 10Gy). 3 fractions are allowed for centrally located tumors

Dose # 2 of durvalumab, (post SBRT) to be given 1-10 days post last SBRT. Durvalumab then to be given at 10mg/kg Q2 weeks (+/- 4 days) for a total of 12 months (maximum of 26 treatments total)

Drug: Durvalumab
Durvalumab10mg/kg Q2 weeks (+/- 4 days) for a total of 12 months (maximum of 26 treatments total)
Other Name: Imfinzi

Radiation: SBRT

SBRT boost will consist of 2 fractions delivered to the primary tumor only, over 1-2 weeks between the first and second treatments with durvalumab.

The dose will consist of 20Gy (2 fractions of 10Gy)

*3 fractions are allowed for centrally located tumors

Other Name: Stereotactic body radiation




Primary Outcome Measures :
  1. Number of patients experiencing grade 2 or higher toxicities during consolidation SBRT with concurrent durvalumab after chemoradiation for locally advanced stage III NSCLC [ Time Frame: Defined as the first 3 months of durvalumab. ]
    This outcome will examine the safety and tolerability of the trial.

  2. Average progression-free survival of chemoradiation followed by SBRT and durvalumab for patients with locally advanced stage III NSCLC. [ Time Frame: Every 3 months for 1 year then every 4 months for two years then every 6 months for two years then annually until progression on average for about 5 years. ]
    RECIST 1.1


Secondary Outcome Measures :
  1. Overall survival (OS) [ Time Frame: Every 2 months for the first 6 months, then every 4 months for 2 years then every 6 months for 2 years then yearly for about 5 years ]
  2. Average time to local-regional progression (LRP) [ Time Frame: Every 3 months for 1 year then every 4 months for two years then every 6 months for two years then annually until progression for about 5 years. ]
  3. Time to distant metastasis (DM) [ Time Frame: Every 3 months for 1 year then every 4 months for two years then every 6 months for two years then annually until progression. ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Stage III NSCLC.
  • Completion of concurrent chemoradiation:

    • Radiation dose of 60.0 Gy (50-65Gy) using standard fractionation

  • Patients will receive the first dose of durvalumab > 3 weeks and < 7 weeks after their last treatment of chemoradiation (last radiation or chemotherapy treatment, whichever ended last).Sites are required to submit prior treatment (chemotherapy and radiation)
  • Residual tumor volume that is appropriate for SBRT

    • Residual Primary tumor <120cc (approximately 6cm diameter).

  • Absolute neutrophil count ≥ 1,000/uL, platelet ≥ 60,000/uL prior to registration.
  • Total bilirubin ≤ 1.5x upper institutional limit of normal (ULN), and AST and ALT ≤ 3x ULN.
  • ECOG performance status 0 to 1
  • Minimum life expectancy of 12 weeks as determined by treating physician.
  • Age > 18 years.
  • Voluntary, signed written informed consent.
  • Women of childbearing potential must have a negative serum pregnancy test within 7 days of day 1 of treatment (post-menopausal women, defined as surgical menopause or lack or menses >12 months, do not need to have a pregnancy test, document status.)
  • Men and women of childbearing potential must be willing to consent to using effective contraception while on treatment and for at least 6 months after the last treatment.
  • Resolution of all related toxicities from chemo/RT to < grade 2, except alopecia.
  • Patient must have tissue available from prior biopsy for correlative studies as confirmed by treating physician.

Exclusion Criteria:

  • Disease progression during or after standard chemoradiation
  • Prior thoracic radiation (other than the chemoradiation delivered prior to SBRT)
  • Metastatic disease
  • Uncontrolled severe, intercurrent illness as confirmed by the treating physician.
  • Chemotherapy within 3 weeks from the first treatment on study (day 1).
  • Prior complete resection of all NSCLC (patients could have undergone prior resection as long as it is not complete and the patient meets criteria and staging and tumor volume for registration).
  • Severe, active co-morbidity, defined as follows:

    • Uncontrolled neuropathy ≥ grade 2 regardless of cause;
    • Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months;
    • Transmural myocardial infarction within the last 6 months;
    • Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration;
    • Severe hepatic disease, defined as a diagnosis of Child-Pugh Class B or C hepatic disease.
    • HIV positive with CD4 count < 200 cells/microliter. Note that patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count ≥ 200 cells/microliter within 30 days prior to registration. Note also that HIV testing is not required for eligibility for this protocol unless patient is known to be HIV positive and they do not had a CD4 count result within 30 days prior to registration.
  • Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment, not inclusive of patients who are HIV positive and who meet criterion above.

Note: Patients who require continuous or intermittent steroid therapy for non-autoimmune conditions, e.g. asthma, osteoarthritis or intravenous contrast allergy, are eligible permitted those patients who receive continuous steroids are limited to a dose of ≤10 mg/day of prednisone (or equivalent). Higher doses are permitted for intermittent therapy, e.g. for contrast allergy, but will need to be approved by BrUOG prior to registration.

  • Has a known history of active tuberculosis
  • Hypersensitivity to Durvalumab or any of its excipients
  • Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment
  • Has known history of clinically significant pneumonitis
  • Has an active infection requiring intravenous systemic therapy at the time of registration
  • Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating physician
  • Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial as per the treating physician
  • Is pregnant or breastfeeding
  • Has received prior therapy with an anti-CTLA-4, -PD-1, -PD-L1, or -PD-L2 agent
  • Has a known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03589547


Contacts
Layout table for location contacts
Contact: Roxanne Wood, BA 4018633000 roxanne_wood@brown.edu

Locations
Layout table for location information
United States, Rhode Island
Rhode Island Hospital Recruiting
Providence, Rhode Island, United States, 02903
Contact: Roxanne Wood, BA    401-863-3000    roxanne_wood@brown.edu   
Principal Investigator: Hina Khan, MD         
Sub-Investigator: Jaroslaw Hepel, MD         
The Miriam Hospital Recruiting
Providence, Rhode Island, United States, 02906
Contact: Roxanne Wood, BA    401-863-3000    roxanne_wood@brown.edu   
Principal Investigator: Hina Khan, MD         
Sponsors and Collaborators
Hina Khan
Brown University
Lifespan
Investigators
Layout table for investigator information
Principal Investigator: Hina Khan, MD Brown University Oncology Research Group (BrUOG) & Lifespan Cancer Institute
Layout table for additonal information
Responsible Party: Hina Khan, Sponsor-Investigator, Brown University
ClinicalTrials.gov Identifier: NCT03589547    
Other Study ID Numbers: BrUOG 358
First Posted: July 18, 2018    Key Record Dates
Last Update Posted: January 23, 2020
Last Verified: January 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Hina Khan, Brown University:
Lung cancer
NSCLC
Stage III
Post chemoradiation
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Durvalumab
Antineoplastic Agents, Immunological
Antineoplastic Agents